BEGIN:VCALENDAR
PRODID:-//github.com/ical-org/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VTIMEZONE
TZID:America/New_York
X-LIC-LOCATION:America/New_York
BEGIN:STANDARD
DTSTART:20241103T020000
RRULE:FREQ=YEARLY;BYDAY=1SU;BYMONTH=11
TZNAME:EST
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
END:STANDARD
BEGIN:DAYLIGHT
DTSTART:20250309T020000
RRULE:FREQ=YEARLY;BYDAY=2SU;BYMONTH=3
TZNAME:EDT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
END:DAYLIGHT
END:VTIMEZONE
BEGIN:VEVENT
DESCRIPTION:Bio : Yutian Feng is an Assistant Professor of Radiology and M
 edical Physics at Duke University Medical Center. He is a radiochemist by
  training\, and the centerpiece of his research is Astatine-211 targeted 
 alpha therapy for cancer treatment. Yutian's research group has developed
  several At-211 targeted alpha therapy agents that have been licensed to 
 biotech companies and translated clinically. He has published 20+ researc
 h articles\, two book chapters and served as Editor-in-Chief for a book\,
  20+ invited presentations\, and 2 patents that have been licensed. In 20
 20\, he co-founded Alpha Nuclide as a targeted alpha therapy infrastructu
 re biotech company\, and has raised a total of 40 M USD to date. Abstract
  : Targeted radionuclide therapy (TRT) have shown promising results in ca
 ncer treatment and targeted alpha therapy (TAT) in which alpha-particle e
 mitting radionuclides are used as the payload have become the new frontie
 r in this field. Astatine-211 is one of the most promising TAT radionucli
 de. Our group has developed several At-211 TAT agents\, and in this prese
 ntation we will showcase an At-211 PSMA agent and a HER2-targeted agent f
 or prostate cancer and breast cancer treatment\, respectively. In the sec
 ond part of the presentation\, we will discuss the necessary infrastructu
 re needed to reach the potential for At-211 TAT treatment\, and the innov
 ation along the way.\n\nSpeaker:\nYutian Feng\n\nAdmission:\nFree\n\nFood
 :\nCoffee\, Snacks\, Tea: Cookies\, coffee and tea will be provided.\n\nD
 etails URL:\nhttps://medicine.yale.edu/event/bis-as211-targeted-alpha/\n
DTEND;TZID=America/New_York:20260813T140000
DTSTAMP:20260821T162129Z
DTSTART;TZID=America/New_York:20260813T130000
LOCATION:Email contact for zoom link password\, URL: https://yale.zoom.us/
 j/99123292996?pwd=0xZHQPKFYzVsrDnadrr6COjCjZ00Lr.1
SEQUENCE:0
STATUS:Confirmed
SUMMARY:BIS Seminar
UID:43ce3b27-d64d-4d76-85c7-af12a5dc3143
END:VEVENT
END:VCALENDAR